References

A review on various targeted anticancer therapies

10.1007/s11523-012-0212-2 · 2012 · External reference

Vascular targeting as a strategy for cancer therapy

10.1056/nejm199808133390711 · 1998 · External reference

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

10.1126/science.279.5349.377 · 1998 · External reference

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

10.1038/sj.bjc.6601606 · 2004 · External reference

Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome

10.1593/neo.06748 · 2007 · External reference

Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis

10.1593/neo.05739 · 2006 · External reference

Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice

1999 · External reference

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

10.1200/jco.2003.05.185 · 2003 · External reference

Disrupting tumour blood vessels

10.1038/nrc1628 · 2005 · External reference

The clinical development of tubulin binding vascular disrupting agents

2010 · External reference

Unresolved reference

External reference

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds

10.1007/s11912-005-0033-x · 2005 · External reference

Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with micro-angiography and histology

10.1097/rli.0b013e31818e5ace · 2009 · External reference

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

10.1200/jco.2003.05.186 · 2003 · External reference

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

10.1093/annonc/mdq708 · 2011 · External reference

Combretastatin A4 phosphate

10.1097/00001813-200403000-00001 · 2004 · External reference

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability

2001 · External reference

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses

10.1158/1078-0432.ccr-08-2906 · 2009 · External reference

Characterizing the tumor response to treatment with combretastatin A4 phosphate

10.1016/j.ijrobp.2006.12.051 · 2007 · External reference

A dual-targeting anticancer approach: soil and seed principle

10.1148/radiol.11102120 · 2011 · External reference

A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

10.1038/sj.bjc.6605650 · 2010 · External reference

Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors

10.18388/abp.2009_2528 · 2009 · External reference

Phase I trial of combretastatin a-4 phosphate with carboplatin

10.1158/1078-0432.ccr-04-1434 · 2005 · External reference

Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI

10.1371/journal.pone.0041140 · 2012 · External reference

Tumour vascular disrupting agents: combating treatment resistance

10.1259/bjr/36205483 · 2008 · External reference

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses

2002 · External reference

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer

10.1634/theoncologist.2008-0287 · 2009 · External reference

Vascular targeted therapies in oncology

10.1007/s00441-008-0646-0 · 2009 · External reference

Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers

10.1097/cad.0b013e328349dd60 · 2012 · External reference

Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer

10.4329/wjr.v3.i1.1 · 2011 · External reference

Cancer models—multiparametric applications of clinical MRI in rodent hepatic tumor model

10.1007/978-1-61779-219-9_26 · 2011 · External reference

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126

10.1158/1078-0432.ccr-03-0417 · 2004 · External reference

Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126

10.4161/cbt.6.9.4634 · 2007 · External reference

Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging

10.1148/radiol.2372041638 · 2005 · External reference

Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis

10.1148/radiol.2392050277 · 2006 · External reference

A biomathematical approach to clinical tumor growth

10.1002/1097-0142(196111/12)14:6<1272::aid-cncr2820140618>3.0.co;2-h · 1961 · External reference

Diffusion-weightedMRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions

10.1002/jmri.21675 · 2009 · External reference

Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours

10.1007/s00330-010-1743-5 · 2010 · External reference

New guidelines to evaluate the response to treatment in solid tumors

10.1093/jnci/92.3.205 · 2000 · External reference

Evaluation of the response to treatment of solid tumours—a consensus statement of the International Cancer Imaging Society

10.1038/sj.bjc.6601843 · 2004 · External reference

Measurement of tumour response to cancer treatment: morphologic imaging role

2007 · External reference

Multiparametric imaging of tumor response to therapy

10.1148/radiol.10091760 · 2010 · External reference

Measuring tumour vascular response to antivascular and antiangiogenic drugs

10.1259/bjr/30165281 · 2003 · External reference

Effects of intracellular organelles on the apparent diffusion coefficient of water molecules in cultured human embryonic kidney cells

10.1002/mrm.22666 · 2011 · External reference

Rat model of reperfused partial liver infarction: characterization with multiparametric magnetic resonance imaging, microangiography, and histomorphology

10.1080/02841850802647021 · 2009 · External reference

Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer

10.1097/00004424-199209000-00006 · 1992 · External reference

Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma ingrats

10.1148/radiol.2343031721 · 2005 · External reference

Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule

10.1200/jco.2011.39.3934 · 2012 · External reference

Effect of host microenvironment on the microcirculation of human colon adenocarcinoma

1997 · External reference

Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells

10.1002/mc.20388 · 2008 · External reference